Equities Analysts Set Expectations for DYN FY2026 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Investment analysts at HC Wainwright upped their FY2026 EPS estimates for Dyne Therapeutics in a research report issued to clients and investors on Tuesday, March 3rd. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($3.05) per share for the year, up from their previous estimate of ($3.17). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($1.68) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $1.28 EPS and FY2030 earnings at $3.24 EPS.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02).

Other analysts have also issued research reports about the company. Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a research note on Tuesday, December 9th. Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a report on Monday, December 8th. Chardan Capital restated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research note on Monday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $40.00 price objective on shares of Dyne Therapeutics in a research report on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.00.

Dyne Therapeutics Trading Down 0.2%

Shares of NASDAQ:DYN opened at $15.20 on Friday. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.47 and a current ratio of 22.25. The company has a market capitalization of $2.51 billion, a P/E ratio of -4.29 and a beta of 1.34. The company has a 50-day simple moving average of $17.15 and a 200 day simple moving average of $17.03.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. CWM LLC lifted its holdings in shares of Dyne Therapeutics by 168.1% during the second quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after buying an additional 1,900 shares in the last quarter. Chung Wu Investment Group LLC acquired a new position in shares of Dyne Therapeutics in the third quarter valued at about $30,000. Strs Ohio bought a new position in Dyne Therapeutics during the fourth quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in Dyne Therapeutics in the 4th quarter valued at about $84,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a lofty $50 price target, and raised its FY2026 loss forecast slightly (smaller loss, from ($3.17) to ($3.05)) — this keeps a strong upside narrative for longer‑term investors. MarketBeat Report
• Neutral Sentiment: HC Wainwright also published a longer EPS path showing a return to profitability by FY2029–FY2030 (FY2030: $3.24 EPS), which supports a growth thesis but is far‑term and model‑sensitive. MarketBeat Report
• Neutral Sentiment: Reported short interest data is effectively zero/unchanged (likely a reporting quirk) and does not appear to be a market driver.
• Negative Sentiment: HC Wainwright trimmed medium‑term forecasts (FY2027–FY2029 and FY2028 revisions), lowering expected EPS in some years — this reduces near‑term profitability expectations and can weigh on sentiment. MarketBeat Report
• Negative Sentiment: Lifesci Capital made small downward revisions to several quarterly estimates (Q2 and Q4 2026, and others with mixed tweaks), which modestly increases near‑term uncertainty around upcoming results. MarketBeat Report

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.